戻る
Genflow Biosciences plc (GENFF)価格
GENFF 株価推移チャート
GENFF 収入
Genflow Biosciences plc
$0.03
0%
$0
終値： Jan 27, 16:00:00 GMT-5
$0.03
0%
$0
アフターマーケット：Jan 27, 20:00:00 GMT-5
Earnings FAQ
GENFFの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Genflow Biosciences plc GENFFの前四半期の収益はどうでしたか？
Genflow Biosciences plcの収益見積もりはいくらですか？
Genflow Biosciences plcの収益品質スコアはどれくらいですか？
Genflow Biosciences plcはいつ収益を報告しますか？
Genflow Biosciences plcの予想収益はいくらですか？
Genflow Biosciences plcは収益予想を上回りましたか？
主要データ
前終値
$0.0383
始値
$0.0298
当日レンジ
$0.0298 - $0.0383
52週レンジ
$0.01 - $0.0645
取引高
110.0K
平均取引高
13.6K
1株当たり利益(TTM)
-0.01
配当利回り
--
時価総額
$18.9M
Genflow Biosciences Plcとは何ですか？
Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.